Recently, a unique point mutation in the JH2 domain of the Janus kinase 2 gene (JAK2) was identified in several chronic myeloid disorders. This mutation leads to a V617F substitution of phenylalanine for valine in the protein. Affected are more than 80% of polycythemia vera (PV), 40% of essential thrombocythemia (ET) and 40% of idiopathic myelofibrosis (CIM) patients. 1 The non-receptor Janus tyrosine kinases are involved in the signalling pathways of erythropoietin (EPO), thrombopoietin (TPO) und granulocyte colony-stimulating factor (G-CSF) which mediate anti-apoptosis, cell cycle progression and growth. The V617F mutation is located in the JH2 pseudokinase domain of JAK2 which is involved in inhibition of the kinase activity. 2 The mutant JAK2 is auto-phosphorylated in factor-dependent cell lines resulting in a cytokine independent activation of STAT5, ERK/MAP kinase and PI3K/AKT. Therefore, the V617F mutation is regarded as a gain-of-function mutation. 3 Common diagnostic tests for the detection of V617F are sequencing of the respective gene fragment, allele-specific polymerase chain reaction (ASO-PCR) and melting curve analysis using real-time PCR devices in combination with fluorescent hybridization probes.
Here, we describe a novel point mutation located next to V617F in the pseudokinase domain of JAK2.
The genomic DNA of a 27-year-old male patient diagnosed with PV was analyzed for the V617F mutation by an melting curve assay using the LightCycler system (Roche, Mannheim, Germany). 4 During the interpretation of this analysis, a lower melting temperature of the mutation peak as compared to other V617F positive samples or the homozygously mutated HEL cell line was observed (Figure 1 To further analyze the distribution of the V617F and the D620E mutations in the peripheral blood leukocyte subpopulations of this patient, CD15 þ granulocytes, CD14 þ monocytes, CD19
þ B cells and CD3 þ T cells were purified from the mononuclear cells after Ficoll/Paque (Biochrom, Berlin, Germany) density gradient centrifugation using MACS (magnetic associated cell sorting) MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the protocol provided by the manufacturer. Cell populations were characterized by staining with fluorescein isothiocyanate (FITC)/phycoerythrin (PE) monoclonal antibodies and flow cytometry after isolation Letters to the Editor procedures. Purity was found to be approximately 96% in all populations (data not shown).
ASO-PCRs specific for the V617F and D620E mutations were established for the analysis of the DNA purified from the various blood subpopulations. We therefore modified a previously described assay 5 by including an new allele specific primer for D620E (5 0 -tta aat tat gga gta tgt gtc tgt gga aaa-3 0 ). As shown in Figure 3 , the V617F mutation was detected in the patient's whole blood, granulocytes, and monocytes but not in his B or T cells. In contrast, the D620E mutation was detected in all peripheral blood subpopulations analyzed (Figure 3) .
The JAK2 mutation is somatic and occurs at the level of a hematopoietic stem cell. 6 Accordingly, several groups have reported the absence of the JAK2-V617F mutation in B cells and T cells of PV patients indicating that JAK2-V617F mutation is an acquired myeloid lineage-specific mutation.
3,5 However, Ishii et al. 7 recently reported that the JAK2-V617F mutation is not only a myeloid lineage-specific mutation, but is also present in T and B lymphocytes in a subpopulation of patients with PV. In these cases, the mutation is likely to originate at the level of cell capable of generating both lymphoid and myeloid cells.
In the present study, the V617F mutation was detected only in myeloid cells whereas the D620E mutation was found in all peripheral blood subsets including B and T lymphocytes. These findings suggest that in this patient the D620E mutation occurred at the multipotent hematopoietic stem cell level, which gave rise to myeloid and lymphoid hematopoietic lineages. In contrast, the V617F mutation appeared at the stage of a common myeloid progenitor cell, which generated myeloid but not lymphoid cells.
Aspartate and glutamate are both closely related acidic amino acids so that one can speculate that the structural and/or functional impact of the D620E mutation on the JH2 pseudokinase would be minor. Nevertheless, the biological influence of this amino-acid exchange needs to be determined in appropriate assays, especially in combination with the V617F mutation.
Interestingly, the same D620E and an additional mutation E627E was recently described in two patients diagnosed with myeloproliferative disorders. 8 However, in this report, the occurrence of these mutations in blood subpopulations was not analyzed.
Patients with chronic myeloproliferative disorders should now, beside for V617F, also be tested for D620E to determine the incidence and/or correlation with distinct disorders. Furthermore, the cellular distribution of the two JAK2 mutations needs to be analyzed in greater falling numbers. ASO-PCR for the JAK2-V617F and D620E mutations in purified peripheral blood cells from a patient with PV. As a control DNA purified from the leukocytes of a healthy donor were included. PCR reactions (10.0 ml) were electrophoresed through a 3.0% agarose gel and stained with ethidium bromide for visualization under UV light. 
